As previously reported, morphological relapse could be early preceded by molecular relapse. 8 In 11 out of 13 patients in our study with serial MRD assessments, molecular relapse occurred by 35 days to 621 days before morphological relapse (median: 146 days). This time interval may be used to treat relapses at the molecular stage already, before full-blown relapse is observed. Compared with the general population of AML patients, we confirmed the lower incidence of FLT3-ITD and a higher incidence of the c-KIT and RAS mutations in CBFB-MYH11 positive AML. 7 The prognostic impact of any of such mutations is still under debate because of conflicting results, especially for c-KIT mutations. 1,7 In contrast to molecular response, these mutations showed no prognostic value in this study, probably due to the relatively small sample size. Mutational status documentation could however identify populations of patients who could respond to new targeted treatments. On the basis of our results, we are conducting a prospective clinical trial for CBF AML (that is, CBF-2006), in which allogeneic BM transplantation with a matched related donor in first CR is offered to patients who did not achieve a 3-log reduction of CBFB-MYH11 transcript level after the first course of consolidation therapy.
Graft-versus-host driven graft-versus-leukemia effect of minor histocompatibility antigen HA-1 in chronic myeloid leukemia patients Leukemia (2010 Leukemia ( ) 24, 1388 Leukemia ( -1392 doi:10.1038 /leu.2010 published online 27 May 2010 Numerous clinical and experimental studies in human leukocyte antigen (HLA)-matched stem cell transplantation (SCT) provide evidence that both the graft versus leukemia (GvL) effect and graft versus host disease (GvHD) develop as a result of cellular allo-immune responses evoked by disparity of minor histocompatibility antigens (mHags) between recipient and donor. 1 The mHags are polymorphic peptides that are presented on the cell surface by HLA molecules and can induce allo-immune T-cell responses from mHag-negative donors. The mHags are derived from polymorphic cellular proteins expressed either ubiquitously or in a hematopoietic systemspecific manner.
1 Among hematopoietic mHags, the HLA-A2 restricted mHag HA-1 receives most attention; it is highly immunogenic, is frequent in Caucasians, shows high expression in all types of hematological malignancies and aberrant Letters to the Editor expression on various epithelial tumors with no expression in normal epithelial cells.
2 HA-1-specific cytotoxic T lymphocytes (CTLs) lyse all hematopoietic cells including leukemia and myeloma cells in vitro and inhibit human lymphoblastoid leukemia cell outgrowth in a xenogeneic non obese diabetic/ severe combined immunodeficient murine model, 3 suggesting a significant contribution of mHag HA-1 to the GvL effect. Nonetheless, the only clinical evidence suggesting the involvement of HA-1 in GvL and in graft versus myeloma is the emergence of HA-1-specific CTLs in circulation coinciding with tumor regression in chronic myeloid leukemia (CML) and multiple myeloma patients after donor lymphocyte infusions (DLI).
4 Therefore, we here evaluated the putative clinical importance of HA-1 by correlating HA-1 disparity with relapse incidence (RI), overall survival (OS), relapse-free survival (RFS) and non-relapse mortality (NRM) in a relatively large cohort of 285 HLA-A2-positive CML patients who received myeloablative allo-SCT from HLA-identical sibling donors.
The cohort included 156 male and 129 female patients with a median age of 39 (range 14-65). At the time of SCT, 226 (82%) patients presented the CML at chronic phase, 42 (15%) patients showed accelerated phase, 7 (3%) patients showed blast crisis and 12 of them had an unknown phase of the disease. In 54 (23%) cases, recipients received a sex-mismatched transplantation, defined as recipient male-donor female. Other gender combinations were regarded as no sex-mismatch. For all patients and their donors, we determined the HA-1 allelic expression by genomic HA-1 typing using established and verified techniques. 2, 5 As only one of the two HA-1 alleles (HA-1 H ) is immunogenic, 1 HA-1 disparity is defined as the presence of the HA-1 H in the recipient and its absence in the donor. The analyses were carried out only in this defined HA-1-mismatch direction. As expected on the basis of the HA-1 alleles phenotype frequency, 36 of the 285 (13.3%) pairs were HA-1 incompatible. GvHD prophylaxis involved either T-cell depletion (alone or combined with cyclosporine), or cyclosporine (alone or combined with methotrexate). Acute(a) GvHD was graded according to the standard criteria. 6 The occurrence of relapse was based on the information reported by the individual team. In most instances, solely hematological relapse were reported with no further detailed information on cytogenetic and molecular relapse because the international study design within the European Group for Blood and Marrow Transplantation does not provide more detailed information.
Univariate analyses revealed no significant associations between HA-1-disparity status and donor gender, gendermismatch, source of stem cells, CML status at transplant, use of methotrexate or T-cell depletion (data not shown).
Among 271 patients who could be evaluated for aGvHD (Table 1) , univariate analyses showed no association between HA-1 mismatches and the occurrence (odds ratio (OR) ¼ 0.91, P ¼ 0.85) or severity (OR ¼ 1.06, P ¼ 1.0) of aGvHD. Correlation with chronic GvHD was difficult to assess since the timing of cGvHD occurrence was not known; hence, a simple correlation in the cross-tabulation needs to be interpreted very carefully because of the censoring-by-death mechanism (Table 1) . Treating aGvHD as a non-time depending (fixed) variable, we also estimated the effect of HA-1-mismatch on the probability of developing aGvHD in a logistic regression model after adjusting for patient age, T-cell depletion and GvHD prophylaxis. Again, no significant association was found with ORs close to 1 and P-values 40.60 (data not shown). These results clearly showed that, in this cohort, HA-1 disparity was not associated with GvHD.
We then fitted multivariate Cox proportional hazards regression models to determine the possible effect of HA-1 mismatches on RI, OS, RFS and NRM (Table 2, Figure 1) . In these models, we included gender mismatches and variables that might influence the in vivo donor anti-host T-cell reactivity, such as GvHD prophylaxis and T-cell depletion, as independent variables. In addition, we postulated that the occurrence of aGvHD might influence the donor anti-host T-cell reactivity in recipients. Therefore, we also included the interaction between HA-1 mismatches and aGvHD as an independent variable. As T-cell responses can be influenced even by the occurrence of GvHD grade I, we used a no GvHD versus GvHD grade I-IV categorization in these analyses.
Interestingly, the analyses showed a significant interaction between HA-1-mismatch and aGvHD with respect to the probability of relapse (P ¼ 0.02), OS (P ¼ 0.03) and RFS (P ¼ 0.01) but not of NRM (P ¼ 0.53). Accordingly, in the presence of aGvHD, HA-1-mismatch had a strong beneficial effect on the risk of relapse (hazard ratio (HR) ¼ 0.15), and on the OS (HR ¼ 0.31) and RFS (HR ¼ 0.26) rates. No interactions were observed between HA-1 mismatches and cGvHD. We did not observe interactions between sex mismatches and GvHD (data not shown). Although gender mismatches seemed to have a slight negative effect on relapse rates in Cox models (P ¼ 0.05, HR ¼ 1.8) (Table 2 ), in a separate landmark analysis these seemingly negative effects disappeared, and similar to previous studies, gender mismatches were associated with a lower but nonsignificant RI beyond 2 years after transplantation (data not shown).
Taken together, this retrospective clinical study showed a clear association between HA-1 disparity and reduction of the risk of relapse (7.1 times), elongation of the OS and RFS (3.4 and 4.0 times, respectively) in CML patients after HLA-identical SCT, but only in those patients who developed aGvHD. No direct association of HA-1 disparity with aGvHD was observed. Thus, the interaction between HA-1 and aGvHD with respect to RI, OS and RFS is a specific phenomenon and certainly not a simple reflection of an association between HA-1 disparity and GvHD. Moreover, this interaction seems specific for HA-1 as no such interaction was present between gender mismatches and GvHD in this study (data not shown). 
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Previously, two relatively small clinical cohorts, comprising different types of hematological malignancies had addressed the relationship between HA-1 and the GvL effect 5,7 without success. We therefore aimed at studying a large cohort and also restricted our study to one single disease, that is, CML. Namely, we postulated that the effect of mHag mismatches on GvL can be best studied in a model disease known for a good response to cellular immunotherapy such as DLI. To include a large numbers of patients within a reasonable time frame, we chose a retrospective approach and included patients from more than 20 different transplantation centers. Obviously, such a retrospective approach has its limitations. For instance in our study GvHD prophylaxis was heterogeneous; there was no external validation of the GvHD grading and the definition of relapse was not uniform. Therefore, the results need to be interpreted with some caution. Nonetheless, in this first relatively large cohort, the collected data set was adequate to build Cox regression models for analyzing the relation between HA-1 mismatches and GvL and to include important parameters potentially influencing relapse rates and survival. Unique in our study, we also included the possible interaction between GvHD and HA-1-mismatch with respect to GvL, which was indeed the case. Our results inevitably lead to the question whether aGvHD is a mere indicator of donor T-cell reactivity in the patients or does it serve as a driving force for the generation HA-1-specific T cells? With respect to the latter assumption, it is worth noting that a role for GvHD in the generation of tumor-specific T-cell responses has been already suggested by a murine study 8 and two clinical allo-SCT studies. 9,10 Furthermore it has been documented that induction anti-tumor immune responses is possible after vaccination with allogeneic tumor cells 11 or with DNA encoding for allogeneic major histocompatibility complex genes.
12,13 Also worth mentioning are the observations of Sykes et al.
14 that infusion of recipient lymphocytes into mixed chimeric recipients after allo-SCT, initiates an alloreactivity in the host versus graft direction and facilitates the generation of recipient derived anti-tumor T cells. Similarly, it seems plausible that the broad alloreactive response Table 2 Cox proportional hazards regression analysis of risk factors for RI, OS, RFS and NRM depending on the presence or absence of aGvHD Abbreviations: aGvHD, acute GvHD; CI, confidence interval; CML, chronic myeloid leukemia; CP, chronic phase; GvHD, graft vs host disease; HR, hazard ratio; MTX, methotrexate; no CP, accelerated phase, blast crisis or unknown; NRM, non-transplant-related mortality; OS, overall survival; RFS, relapse-free survival; RI, relapse incidence. a The interaction between HA-1-mismatch and GvHD was studied by including the interaction variable 'aGvHD*HA-1-mismatch' in the model. If this term was significant, the HR for HA-1-mismatch is reported separately in case of presence or absence of aGvHD. In case the interaction term was not significant, the model without interaction term was used to estimate the overall HR for the above mentioned risk factors, adjusting for each other. The interaction term is significant for relapse (P ¼ 0.02), OS (P ¼ 0.03) and RFS (P ¼ 0.01) therefore there is a significant effect of HA-1-mismatch, modified by presence of aGVHD. In other words, the HRs for RI (0.14 and 1.95), OS (0.29 and 2.08) and RFS (0.25 and 1.75) differ significantly.
Letters to the Editor leading to aGvHD could be a driving force for the development of GvL-associated HA-1-specific responses. We think it is important to further analyze this intriguing possibility because dendritic cell vaccination strategies 1,2 aiming at stimulating an effective HA-1 response in vivo may well benefit from supplementary addition of immunostimuli or weak antigenic determinants providing necessary signals for generation, expansion and persistence of HA-1-specific tumor-reactive effector T cells.
In conclusion, the present data provide for the first time evidence on the contribution of a single hematopoietic-mHag to the reduction of leukemia relapse rates depending on the occurrence of alloreactive T-cell responses, presumably toward other mHags. These results indicate that a significant benefit may be obtained by HA-1 mismatching of HLA-identical patient and donor, even if the occurrence of GvHD can not be entirely controlled.
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